ERBB2 and breast carcinoma: We evaluated the effect of this drug on three human breast cancer cell lines with different molecular properties: MCF7 (luminal, ER+Pr+Her2−), MDA-MB-231 (TNBC) and MDA-MB-468 (TNBC).